Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial.

PubWeight™: 0.82‹?›

🔗 View Article (PMC 4500209)

Published in Proc Natl Acad Sci U S A on June 22, 2015


Peter J Kuebler1, Megha L Mehrotra2, J Jeff McConnell2, Sara J Holditch3, Brian I Shaw3, Leandro F Tarosso4, Kaitlyn S Leadabrand3, Jeffrey M Milush3, Vanessa A York3, Rui André Saraiva Raposo5, Rex G Cheng3, Emily M Eriksson3, Vanessa McMahan2, David V Glidden6, Stephen Shiboski6, Robert M Grant7, Douglas F Nixon5, Esper G Kallás4

Author Affiliations

1: Division of Experimental Medicine, University of California, San Francisco, CA 94110; peter.kuebler@ucsf.edu.
2: Institute of Virology & Immunology, Gladstone Institutes, San Francisco, CA 94158;
3: Division of Experimental Medicine, University of California, San Francisco, CA 94110;
4: Division of Clinical Immunology and Allergy, University of São Paulo, São Paulo, Brazil 01246;
5: Division of Experimental Medicine, University of California, San Francisco, CA 94110; Department of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC 20037;
6: Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94158;
7: Institute of Virology & Immunology, Gladstone Institutes, San Francisco, CA 94158; Department of Medicine, University of California, San Francisco, CA 94143.

Associated clinical trials:

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men | NCT00458393

Articles cited by this

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65

Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science (1992) 9.30

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med (2009) 7.33

Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis (2008) 4.47

A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis (2007) 3.95

HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology (2008) 3.72

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 3.71

Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest (1998) 3.53

Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. Immunity (2013) 3.38

Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis (1992) 3.27

Immune clearance of highly pathogenic SIV infection. Nature (2013) 3.15

HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet (1993) 2.71

HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol (2000) 2.69

Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis (2012) 2.18

CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest (2001) 2.15

Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A (2005) 2.10

Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest (2001) 1.85

Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS One (2006) 1.73

Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain. J Virol (2001) 1.29

HIV-1-specific cellular immune responses among HIV-1-resistant sex workers. Immunol Cell Biol (2000) 1.29

T-helper cell responses to HIV envelope peptides in cord blood: protection against intrapartum and breast-feeding transmission. AIDS (2001) 1.23

Determinants of protection among HIV‐exposed seronegative persons: an overview. J Infect Dis (2010) 1.13

T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J Virol (2010) 1.11

Escape from CD8(+) T cell responses in Mamu-B*00801(+) macaques differentiates progressors from elite controllers. J Immunol (2012) 1.07

Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals. J Virol (2011) 1.02

Most highly exposed seronegative men lack HIV-1-specific, IFN-gamma-secreting T cells. J Immunol (2003) 1.01

HIV-1 Env-specific cytotoxic T-lymphocyte responses in exposed, uninfected Kenyan sex workers: a prospective analysis. AIDS (2004) 1.00

Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. PLoS Genet (2014) 1.00

HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell Host Microbe (2014) 0.97

Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(+) T-cell responses which can be defined to the epitope level. Clin Vaccine Immunol (2008) 0.96

Outcomes of a National Institute of Allergy and Infectious Diseases Workshop on understanding HIV-exposed but seronegative individuals. AIDS Res Hum Retroviruses (2011) 0.93

HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. PLoS Pathog (2013) 0.90

Distinct patterns of peripheral HIV-1-specific interferon- gamma responses in exposed HIV-1-seronegative individuals. J Infect Dis (2004) 0.90

Lack of detectable HIV-1-specific CD8(+) T cell responses in Zambian HIV-1-exposed seronegative partners of HIV-1-positive individuals. J Infect Dis (2010) 0.90

Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study. J Infect Dis (2013) 0.88

Dendritic cell amplification of HIV type 1-specific CD8+ T cell responses in exposed, seronegative heterosexual women. AIDS Res Hum Retroviruses (2002) 0.88

Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons. J Infect Dis (2014) 0.83

Unexpected diversity of cellular immune responses against Nef and Vif in HIV-1-infected patients who spontaneously control viral replication. PLoS One (2010) 0.82

Decay kinetics of HIV-1 specific T cell responses in vertically HIV-1 exposed seronegative infants. Front Immunol (2012) 0.77